Please assess the completion status of the following clinical trial:

Trial Title: Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with suspected AD, MCI and other cognitive impairment will be referred by their neurologist to have a clinical ordered FDG-PET/CT and clinically indicated AMYVID in addition,~* Patients equal to or greater than 21 years old,~* Signed informed consent by patient or legal guardian,~* Physically capable to cooperate.~Exclusion Criteria:~* Subjects who do not meet the above mentioned inclusion criteria,~* Subjects unwilling or unable to sign the informed consent form,~* Subjects with any significant psychiatric or neurologic disorder or disease other than dementia expected to interfere with the study,~* Subjects unable to undergo MR scanning due to exclusion via UHCMC MR restrictions (e.g. certain implanted metallic or electronic devices),~* History of adverse events related to a previous MR or PET/CT,~* Pregnant women,~* Minors.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET/CT vs. PET/MRI (Type: OTHER): Patients will be included if presenting with the clinical suspicious of AD, Mild Cognitive Impairment (MCI) or other cognitive impairment to be further determined.~Patients will undergo two doubles scans in two steps with a maximum of 2 week between both: the first step will be one day double scan with FDG imaged by PET-CT and PET-MRI; and the second step will be one day double scan with 18F-florbetapir imaged by PET-CT and PET-MRI at a different timepoints as shown in figure 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).